文献速递咽喉与嗓音

丝裂霉素-C对人声带成纤维细胞的抗纤维化作用

Antifibrotic effect of mitomycin-C on human vocal cord fibroblasts.
PubMed 文献 · Laryngoscope · 2019-01-07

研究从全喉切除术患者声带标本分离人原代成纤维细胞,与MRC-5成纤维细胞共同经5 ng/mL TGF-β及0.5 µg/mL丝裂霉素-C处理24小时,发现丝裂霉素-C可部分逆转TGF-β诱导的成纤维细胞向肌成纤维细胞转化,并降低α-SMA表达和细胞迁移活性。

要点

  • 丝裂霉素-C可部分逆转TGF-β诱导的人声带成纤维细胞向肌成纤维细胞转化。
  • 丝裂霉素-C处理后TGF-β诱导的成纤维细胞α-SMA表达和伤口愈合活性显著降低。
  • 喉气管狭窄患者组织标本病理检查支持上述体外实验结果。

核心结论

  • 丝裂霉素-C在人MRC-5细胞系和人原代声带成纤维细胞培养中显示出抗纤维化作用,可部分逆转肌成纤维细胞表型。

研究设计与样本

  • 体外实验:从全喉切除术患者声带标本分离人原代成纤维细胞,并与MRC-5人成纤维细胞共同处理。
  • 细胞经5 ng/mL TGF-β单独处理,再经0.5 µg/mL丝裂霉素-C处理24小时。
  • 采用α-SMA免疫组化、Western blot和实时聚合酶链反应检测分化,伤口愈合实验评估细胞迁移。
  • 另对一例喉气管狭窄患者的组织标本进行病理检查。

主要发现

  • TGF-β暴露后观察到α-SMA mRNA和蛋白表达升高以及细胞迁移增加。
  • 丝裂霉素-C处理后,TGF-β诱导的成纤维细胞α-SMA表达和伤口愈合活性显著降低。
  • TGF-β刺激的成纤维细胞向肌成纤维细胞转化至少被丝裂霉素-C部分逆转。
  • 喉气管狭窄患者组织标本的病理检查支持上述发现。

关键数值与推荐

  • 丝裂霉素-C使用浓度为0.5 µg/mL,处理时间为24小时。
  • TGF-β使用浓度为5 ng/mL。

临床怎么用

  • 原文结论认为丝裂霉素-C可通过逆转肌成纤维细胞表型成功逆转上气道狭窄。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Acquired laryngotracheal stenosis is a potentially life-threatening situation and a very difficult and challenging problem in laryngology. Therefore, new trends and innovative approaches based on antifibrotic drugs and minimally invasive regimens are being developed to attenuate laryngotracheal fibrosis and scarring. The purpose of this study was to examine the efficacy of mitomycin-C (MMC) to reverse the transforming growth factor (TGF)-β-induced differentiation of MRC-5 fibroblast and human primary vocal cord fibroblasts to reveal the possible applicability of MMC to laryngotracheal fibrotic conditions. METHODS: Human primary fibroblast cells were isolated from vocal cord specimens of patients undergoing total laryngectomy. The established primary vocal cord fibroblast cell cultures as well as the MRC-5 human fibroblast cells were treated with 5 ng/mL TGF-β alone and then with 0.5 µg/mL MMC for 24 hours. Differentiation of fibroblasts was characterized by α-smooth muscle actin (α-SMA) immunhistochemistry, Western blot analysis, and real-time polymerase chain reaction. Cell motility was assessed by wound-healing assay. RESULTS: Elevated α-SMA mRNA and protein expression as well as increased cell motility were observed upon TGF-β exposures. However, after MMC treatments the TGF-β-induced fibroblasts exhibited a significant decrease in α-SMA expression and wound-healing activity. Therefore, TGF-β-stimulated fibroblast-myofibroblast transformation was reversed at least in part by MMC treatment. Histopathological examinations of tissue specimens of a laryngotracheal stenosis patient supported these findings. CONCLUSION: Antifibrotic effects of MMC were demonstrated on the human MRC-5 cell line and on primary vocal cord fibroblast cultures. These results verify that MMC can be used with success to reverse upper airway stenosis by reverting the myofibroblast phenotype. LEVEL OF EVIDENCE: NA Laryngoscope, 129:E255-E262, 2019.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Szabó D, Kovács D, Endrész V, et al. Antifibrotic effect of mitomycin-C on human vocal cord fibroblasts. Laryngoscope. 2019. PMID: 30618152. doi:10.1002/lary.27657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。